Unintentional ingestion of recreational drugs among young children, 2000–2024 Authors: Kristen Uskovich, Hannah L. Hays, Jaahnavi Badeti, Natalie I. Rine, Nichole L. Michaels, Kele Ding, Gary A. Smith Published: 2026 ABSTRACT BackgroundPrevious studies of pediatric recreational drug exposures have often been limited in scope. Given the rapidly changing recreational drug supply and the related unintentional ingestion of these drugs by young children, a comprehensive study that includes recent data about these exposures is needed. The objective of this study is to investigate the characteristics and trends of unintentional ingestions of recreational drugs by children < 6 years old.MethodsUsing a retrospective cohort study design, National Poison Data System data from 2000 to 2024 were analyzed. United States Census Bureau data were used to calculate population-based ingestion rates. Rate ratios (RRs) with 95% confidence intervals (CIs) were calculated to assess the magnitude of relationships between key characteristics and outcomes, such as highest level of health care received and medical outcome.ResultsThere were 41,612 unintentional ingestions involving recreational drugs among children < 6 years old reported to United States poison centers from 2000 to 2024. Most were among children < 3 years old (57.6%), involved a single substance (95.9%), and occurred in a residence (96.4%). Although 50.6% of children experienced no or minor effects, 5.0% had a major effect and there were six deaths. Children < 3 years old were more likely to experience a major effect (RR: 1.54; 95% CI:1.39–1.71) or be admitted to a critical care unit (RR: 1.23; 95% CI: 1.16–1.30) than children 3–5 years old. Cannabinoids accounted for 84.7% of ingestions, followed by stimulants (8.4%), psychedelics (3.5%), opioids (2.8%), and dissociative agents (0.6%). Ingestions involving opioids (RR: 2.60; 95% CI: 2.36–2.86), stimulants (RR: 2.16; 95% CI: 2.01–2.31), and dissociative agents (RR: 1.59; 95% CI: 1.23–2.06) were more likely to be admitted to a critical care unit than the other substance categories combined. The recreational drug ingestion rate per 100,000 US children < 6 years old increased 3,307% from 1.05 in 2000 to 35.91 in 2024, with a rapid increase beginning in 2013, especially involving edible marijuana and psilocybin products.ConclusionsThe recreational drug ingestion rate among children < 6 years old reported to United States poison centers increased substantially from 2000 to 2024. Additional efforts are needed to prevent these unintentional ingestions in this vulnerable population.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12889-026-28233-z. Background Among the more than 2 million exposure calls to United States (US) poison centers (PCs) in 2023, approximately 829,000 (39.8%) involved children < 6 years old, an age group that frequently experiences unintentional ingestions associated with exploratory behavior in the home [1]. These include ingestions of recreational drugs [2–11]. Previous research on this topic has often focused on unintentional cannabis ingestions, which have increased during recent years, associated with state legalization of cannabis and increased availability of edible cannabis products [2–5]. Research also has investigated nonfatal pediatric exposures to fentanyl [7], and increases in deaths and major effects following opioid ingestions among young children [8, 12]. However, studies on pediatric recreational drug exposures have often not been national in scope [3, 4, 9], were focused on a single class of substances such as cannabis [2, 5, 10, 11, 13], opioids [7, 8], or psilocybin [14–16], or combined older children or adolescent age groups with young children [7, 16]. In addition, national studies of pediatric recreational drug exposures have focused on emergency department visits, hospitalizations, or child fatality reviews using databases other than reports to US PCs [7, 12, 17, 18]. Although Graham, et al. [6] investigated pediatric exposures to multiple illicit substances reported to PCs using the National Poison Data System (NPDS), they evaluated children < 10 years old and included data only through 2016. Given the rapidly changing recreational drug supply and the related unintentional access to these drugs by young children, there is a need for a comprehensive analysis of unintentional ingestions among young children that includes more recent data. The objective of this study is to investigate the characteristics and trends of unintentional ingestions of recreational drugs by children < 6 years old reported to US PCs from 2000 to 2024. Methods Data sources We performed a retrospective review of data obtained from the NPDS, which serves as the data warehouse for US PCs and is maintained by the America’s Poison Centers [1, 19]. Data from calls to PCs are entered by Specialists in Poison Information into an electronic medical record for each exposure event, which are then uploaded to the NPDS database in near real-time. In addition to NPDS data, we obtained de-identified detailed clinical narratives regarding the six fatalities in this study from the reporting PCs via America’s Poison Centers. National population estimates were obtained from the US Census Bureau and were used to calculate population-based rates (including age- and sex-specific rates) of exposure per 100,000 US population [20–22]. In accordance with the Declaration of Helsinki, this study was determined to be exempt by the institutional review board of the authors’ institution. Case selection criteria Ingestions of selected recreational drugs among children < 6 years old were included in this study if they involved 1) exploratory behavior (i.e., the reason for exposure was coded as “unintentional – general” in the NPDS), 2) the recreational drug was the primary substance, and 3) the ingestion was directly reported to a US PC from January 1, 2000, through December 31, 2024. A “primary” substance is the substance that is most likely to be responsible for the observed clinical effects, based on the judgement of PC personnel. The ingestion may have involved either a single substance or multiple substances, as long as the primary substance was among the selected recreational drugs included in this study. Exclusion of multiple-substance exposures that included one of the selected recreational drugs that was not ranked as the primary substance resulted in exclusion of 3.0% (n = 1,286) of the exposures. Information about laboratory confirmation of the involved substances was not included in the study dataset. The NPDS assigns a generic code and may assign a product code to each substance. The NPDS defines a generic code as “a code that represents a broad group of related products” and a product code as “a code specific to the exact substance or product by brand name, concentration, and formulation.” A generic code “allows for groupings of related product codes (each product code is assigned to only one generic code)” [23]. Based on their NPDS generic and associated product codes, the following recreational drugs were included in this study: 1) cannabinoids (includes marijuana preparations, semi-synthetic cannabinoids, and synthetic cannabinoids), 2) stimulants (includes cocaine, methamphetamine, and hallucinogenic amphetamines), 3) psychedelics (includes lysergic acid diethylamide, psilocybin and psilocin-containing mushrooms and processed products, and peyote/mescaline), 4) opioids (includes heroin and fentanyl), and 5) dissociative agents (includes ketamine and analogs, and phenylcyclohexylpiperidine/phencyclidine). For the purposes of this study, we combined the NPDS categories: a) “mushrooms, processed preparations: psilocybin containing,” b) “group 6 mushrooms: hallucinogens (psilocybin and psilocin),” and c) mushroom-related products coded under “unknown stimulants or street drugs” into a single category called “psilocybin and psilocin-containing mushrooms and processed products,” which was including under the psychedelics category above. We chose not to differentiate prescription fentanyl and nonprescription fentanyl during analyses because of potential NPDS coding misclassification as identified by Jaworski [24]. The terms “marijuana” and “cannabis” are used interchangeably in this article and refer to delta-9 tetrahydrocannabinol products. Based on their NPDS generic and product codes, marijuana preparations were sub-categorized into “edible preparations” and “other preparations” during analyses (Appendix). Deaths reported through the NPDS undergo extensive formal review and the involved substances are assigned a “relative contribution to fatality” classification by the PC and America’s Poison Centers: 1) undoubtedly responsible, 2) probably responsible, 3) contributory, 4) probably not responsible, 5) clearly not responsible, or 6) unknown. America’s Poison Centers considers a fatality to be exposure-related if its fatality review team judges the substance exposure to be at least contributory (i.e., relative contribution to fatality 1, 2, or 3) [1]. One fatality was excluded from this study because the PC coded the relative contribution to fatality of the primary substance as “probably not responsible” and the determination by America’s Poison Centers was missing. Exposures with a medical outcome of “unrelated effect” (n = 308) or “confirmed non-exposure” (n = 424) were also excluded from the study. Study variables Study variables included year of exposure, child’s age and sex, location of ingestion, ingestion type (single-substance or multiple-substance), highest level of health care received, medical outcome, and substance category and subcategory. The highest level of health care received is categorized by the NPDS [23] as: 1) no treatment received in a healthcare facility, 2) treated/evaluated and released, 3) admitted to critical care unit, 4) admitted to non-critical care unit, 5) refused referral/did not arrive at a healthcare facility, and 6) other/unknown (includes individuals admitted to a psychiatric facility or lost to follow-up or who left against medical advice). Admissions to a critical care unit or non-critical care unit were combined into a single category “medical admissions” during analyses. Medical outcome is categorized by the NPDS [23] as: 1) no effect, 2) minor effect (minimal symptoms that typically resolve quickly), 3) moderate effect (more pronounced, prolonged, or systemic symptoms than minor effect), 4) major effect (symptoms are life-threatening or result in significant disability or disfigurement), 5) death, 6) not followed (includes judged as a non-toxic exposure or minimal clinical effects possible), and 7) unknown (unable to follow, judged as a potentially toxic exposure). Statistical analysis Statistical analyses were performed with IBM SPSS Statistics for Windows, version 29.0 (IBM Corp., Armonk, NY., USA) and SAS 9.4 (SAS Institute, Inc. Cary, North Carolina). The unit of analysis was the reported exposure event. Descriptive statistics and population-based exposure rates were calculated. Piecewise and simple linear regression were used, as appropriate, to determine the statistical significance of rate trends by evaluating whether the null hypothesis of slope = 0 could be rejected using Student’s t-test. The level of significance was α = 0.05. Consistent with our study’s retrospective cohort design, we calculated risk ratios (RRs) with corresponding 95% confidence intervals (CIs) to assess the magnitude of associations between key characteristics (e.g., age, ingestion type, and substance category or subcategory) and outcomes (e.g., highest level of health care received and medical outcome). Results General characteristics There were 41,612 ingestions among children < 6 years old involving selected recreational drugs as the primary substance reported to US PCs from 2000 to 2024 (Table 1). Almost half of ingestions were accounted for by 2-year-old (26.1%) and 1-year-old (23.1%) children, and 51.1% of ingestions were among males. Most (95.9%) ingestions involved a single substance, and the proportion of single-substance ingestions increased slightly with increasing age. Most ingestions (96.4%, n = 40,096) occurred in a residence. Table 1Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by child age, 2000–2024CharacteristicsChild Age< 1 Yearn (%) a1 Yearn (%) a2 Yearsn (%) a3 Yearsn (%) a4 Yearsn (%) a5 Yearsn (%) aUnknown b n Totaln (%) aChild Sex Male1,738 (49.9)4,842 (50.8)5,206 (48.6)4,175 (51.9)2,929 (53.1)2,089 (55.0)4621,025 (51.1) Female1,743 (50.1)4,694 (49.2)5,507 (51.4)3,864 (48.1)2,588 (46.9)1,710 (45.0)4120,147 (48.9) Unknown35609892744536440Ingestion Type Single-substance3,299 (93.8)9,062 (94.4)10,359 (95.8)7,884 (97.0)5,450 (97.5)3,736 (97.2)12339,913 (95.9) Multiple-substance217 (6.2)534 (5.6)452 (4.2)247 (3.0)141 (2.5)108 (2.8)01,699 (4.1)Highest Level of Health Care No healthcare facility treatment773 (25.1)1,648 (19.8)1,740 (19.3)1,215 (18.1)808 (17.1)575 (18.2)286,787 (19.4) Treated/evaluated and released961 (31.2)3,193 (38.4)3,629 (40.2)2,789 (41.6)2,006 (42.4)1,417 (44.9)1214,007 (40.0) Medical admission c1,121 (36.4)2,933 (35.3)2,796 (31.0)2,070 (30.8)1,471 (31.1)878 (27.8)311,272 (32.2) Admitted to critical care unit447 (14.5)1,165 (14.0)1,057 (11.7)740 (11.0)519 (11.0)293 (9.3)24,223 (12.0) Admitted to non-critical care unit674 (21.9)1,768 (21.3)1,739 (19.3)1,330 (19.8)952 (20.1)585 (18.5)17,049 (20.1) Refused referral d221 (7.2)541 (6.5)854 (9.5)637 (9.5)442 (9.4)289 (9.2)132,997 (8.6) Other/Unknown e4401,2811,7921,420864685676,549Medical Outcome No effect659 (21.9)1,554 (19.1)1,536 (17.7)1,079 (16.7)670 (14.8)450 (14.7)95,957 (17.6) Minor effect770 (25.6)2,562 (31.5)2,864 (33.1)2,243 (34.7)1,630 (35.9)1,127 (36.9)1011,206 (33.0) Moderate effect812 (27.0)2,390 (29.3)2,652 (30.6)2,081 (32.2)1,519 (33.2)986 (32.3)510,445 (30.8) Major effect221 (7.3)528 (6.5)409 (4.7)271 (4.2)158 (3.5)103 (3.4)01,690 (5.0) Death1 (0.0)4 (0.1)1 (0.0)0 (0.0)0 (0.0)0 (0.0)06 (0.0) Not followed f547 (18.2)1,108 (13.6)1,203 (13.9)791 (12.2)559 (12.3)389 (12.7)224,619 (13.6) Unknown g5061,4502,1461,6661,055789777,689Substance Category Cannabinoids2,328 (66.2)7,472 (77.9)9,382 (86.8)7,329 (90.1)5,104 (91.3)3,528 (91.8)9435,237 (84.7) Stimulants751 (21.4)1,223 (12.7)770 (7.1)377 (4.6)215 (3.9)132 (3.4)203,488 (8.4) Psychedelics106 (3.0)366 (3.8)342 (3.2)297 (3.7)199 (3.6)137 (3.6)71,454 (3.5) Opioids282 (8.0)436 (4.5)253 (2.3)103 (1.3)57 (1.0)34 (0.9)21,167 (2.8) Dissociative agents49 (1.4)99 (1.0)64 (0.6)25 (0.3)16 (0.3)13 (0.3)0266 (0.6) Total (row %) h3,516 (8.5)9,596 (23.1)10,811 (26.1)8,131 (19.6)5,591 (13.5)3,844 (9.3)12341,612 (100.0)a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentagesb Unknown age includes “unknown ≤5 years old”c Includes admission to a critical care unit or non-critical care unitd Includes “refused referral” and “did not arrive at a healthcare facility”e Includes individuals lost to follow-up or who left against medical advice, and those admitted to a psychiatric facilityf Includes “not followed (minimal clinical effects possible)” and “not followed (judged as non-toxic exposure)”g Includes “unable to follow (judged as a potentially toxic exposure)”h Row percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages Table 1Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by child age, 2000–2024CharacteristicsChild Age< 1 Yearn (%) a1 Yearn (%) a2 Yearsn (%) a3 Yearsn (%) a4 Yearsn (%) a5 Yearsn (%) aUnknown b n Totaln (%) aChild Sex Male1,738 (49.9)4,842 (50.8)5,206 (48.6)4,175 (51.9)2,929 (53.1)2,089 (55.0)4621,025 (51.1) Female1,743 (50.1)4,694 (49.2)5,507 (51.4)3,864 (48.1)2,588 (46.9)1,710 (45.0)4120,147 (48.9) Unknown35609892744536440Ingestion Type Single-substance3,299 (93.8)9,062 (94.4)10,359 (95.8)7,884 (97.0)5,450 (97.5)3,736 (97.2)12339,913 (95.9) Multiple-substance217 (6.2)534 (5.6)452 (4.2)247 (3.0)141 (2.5)108 (2.8)01,699 (4.1)Highest Level of Health Care No healthcare facility treatment773 (25.1)1,648 (19.8)1,740 (19.3)1,215 (18.1)808 (17.1)575 (18.2)286,787 (19.4) Treated/evaluated and released961 (31.2)3,193 (38.4)3,629 (40.2)2,789 (41.6)2,006 (42.4)1,417 (44.9)1214,007 (40.0) Medical admission c1,121 (36.4)2,933 (35.3)2,796 (31.0)2,070 (30.8)1,471 (31.1)878 (27.8)311,272 (32.2) Admitted to critical care unit447 (14.5)1,165 (14.0)1,057 (11.7)740 (11.0)519 (11.0)293 (9.3)24,223 (12.0) Admitted to non-critical care unit674 (21.9)1,768 (21.3)1,739 (19.3)1,330 (19.8)952 (20.1)585 (18.5)17,049 (20.1) Refused referral d221 (7.2)541 (6.5)854 (9.5)637 (9.5)442 (9.4)289 (9.2)132,997 (8.6) Other/Unknown e4401,2811,7921,420864685676,549Medical Outcome No effect659 (21.9)1,554 (19.1)1,536 (17.7)1,079 (16.7)670 (14.8)450 (14.7)95,957 (17.6) Minor effect770 (25.6)2,562 (31.5)2,864 (33.1)2,243 (34.7)1,630 (35.9)1,127 (36.9)1011,206 (33.0) Moderate effect812 (27.0)2,390 (29.3)2,652 (30.6)2,081 (32.2)1,519 (33.2)986 (32.3)510,445 (30.8) Major effect221 (7.3)528 (6.5)409 (4.7)271 (4.2)158 (3.5)103 (3.4)01,690 (5.0) Death1 (0.0)4 (0.1)1 (0.0)0 (0.0)0 (0.0)0 (0.0)06 (0.0) Not followed f547 (18.2)1,108 (13.6)1,203 (13.9)791 (12.2)559 (12.3)389 (12.7)224,619 (13.6) Unknown g5061,4502,1461,6661,055789777,689Substance Category Cannabinoids2,328 (66.2)7,472 (77.9)9,382 (86.8)7,329 (90.1)5,104 (91.3)3,528 (91.8)9435,237 (84.7) Stimulants751 (21.4)1,223 (12.7)770 (7.1)377 (4.6)215 (3.9)132 (3.4)203,488 (8.4) Psychedelics106 (3.0)366 (3.8)342 (3.2)297 (3.7)199 (3.6)137 (3.6)71,454 (3.5) Opioids282 (8.0)436 (4.5)253 (2.3)103 (1.3)57 (1.0)34 (0.9)21,167 (2.8) Dissociative agents49 (1.4)99 (1.0)64 (0.6)25 (0.3)16 (0.3)13 (0.3)0266 (0.6) Total (row %) h3,516 (8.5)9,596 (23.1)10,811 (26.1)8,131 (19.6)5,591 (13.5)3,844 (9.3)12341,612 (100.0)a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentagesb Unknown age includes “unknown ≤5 years old”c Includes admission to a critical care unit or non-critical care unitd Includes “refused referral” and “did not arrive at a healthcare facility”e Includes individuals lost to follow-up or who left against medical advice, and those admitted to a psychiatric facilityf Includes “not followed (minimal clinical effects possible)” and “not followed (judged as non-toxic exposure)”g Includes “unable to follow (judged as a potentially toxic exposure)”h Row percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by child age, 2000–2024 a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages b Unknown age includes “unknown ≤5 years old” c Includes admission to a critical care unit or non-critical care unit d Includes “refused referral” and “did not arrive at a healthcare facility” e Includes individuals lost to follow-up or who left against medical advice, and those admitted to a psychiatric facility f Includes “not followed (minimal clinical effects possible)” and “not followed (judged as non-toxic exposure)” g Includes “unable to follow (judged as a potentially toxic exposure)” h Row percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages Highest level of health care received Most ingestions did not receive treatment in a health care facility (19.4%) or were treated/evaluated and released (40.0%) (Table 1). However, 32.2% of ingestions were medically admitted, including 12.0% to a critical care unit. The proportion of critical care unit admissions decreased with increasing age, from 14.5% among < 1-year-olds to 9.3% among 5-year-olds. Children < 3 years old were more likely to be medically admitted (RR: 1.11; 95% CI:1.07–1.14), and specifically, admitted to a critical care unit (RR: 1.23; 95% CI: 1.16–1.30) than children 3–5 years old. Most (62.0%) multiple-substance ingestions were associated with medical admission (including 31.5% to a critical care unit) compared with 30.7% of single-substance exposures (including 11.1% to a critical care unit) (Table 2). Multiple-substance exposures were twice as likely to be associated with medical admission (RR: 2.02; 95% CI: 1.94–2.10) and 2.8 times as likely to be associated with a critical care unit admission (RR: 2.83; 95% CI: 2.62–3.06) compared with single-substance ingestions. Table 2Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by ingestion type, 2000–2024CharacteristicsIngestion TypeSingle-substancen (%) aMultiple-substancen (%) aChild Age <1 Year3,299 (8.3)217 (12.8) 1 Year9,062 (22.8)534 (31.4) 2 Years10,359 (26.0)452 (26.6) 3 Years7,884 (19.8)247 (14.5) 4 Years5,450 (13.7)141 (8.3) 5 Years3,736 (9.4)108 (6.4) Unknown b1230Child Sex Male20,119 (51.0)906 (53.6) Female19,363 (49.0)784 (46.4) Unknown4319Highest Level of Health Care Received No treatment received in a healthcare facility6,688 (20.0)99 (6.1) Treated/evaluated and released13,515 (40.4)492 (30.2) Medical admission c10,261 (30.7)1,011 (62.0) Admitted to a critical care unit3,710 (11.1)513 (31.5) Admitted to a non-critical care unit6,551 (19.6)498 (30.5) Refused referral d2,968 (8.9)29 (1.8) Other/Unknown e6,48168Medical Outcome No effect5,815 (18.0)142 (8.8) Minor effect10,799 (33.4)407 (25.2) Moderate effect9,749 (30.2)696 (43.1) Major effect1,391 (4.3)299 (18.5) Death3 (0.0)3 (0.2) Not followed f4,551 (14.1)68 (4.2) Unknown g7,60584Total (Row %)39,913 (95.9)1,699 (4.1)a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentagesb Unknown age includes “unknown ≤5 years old”c Includes admission to a critical care unit or non-critical care unitd Includes “refused referral” and “did not arrive at a healthcare facility”e Includes individuals lost to follow-up or who left against medical advice, and those admitted to a psychiatric facilityf Includes “not followed (minimal clinical effects possible)” and “not followed (judged as non-toxic exposure)”g Includes “unable to follow (judged as a potentially toxic exposure)” Table 2Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by ingestion type, 2000–2024CharacteristicsIngestion TypeSingle-substancen (%) aMultiple-substancen (%) aChild Age <1 Year3,299 (8.3)217 (12.8) 1 Year9,062 (22.8)534 (31.4) 2 Years10,359 (26.0)452 (26.6) 3 Years7,884 (19.8)247 (14.5) 4 Years5,450 (13.7)141 (8.3) 5 Years3,736 (9.4)108 (6.4) Unknown b1230Child Sex Male20,119 (51.0)906 (53.6) Female19,363 (49.0)784 (46.4) Unknown4319Highest Level of Health Care Received No treatment received in a healthcare facility6,688 (20.0)99 (6.1) Treated/evaluated and released13,515 (40.4)492 (30.2) Medical admission c10,261 (30.7)1,011 (62.0) Admitted to a critical care unit3,710 (11.1)513 (31.5) Admitted to a non-critical care unit6,551 (19.6)498 (30.5) Refused referral d2,968 (8.9)29 (1.8) Other/Unknown e6,48168Medical Outcome No effect5,815 (18.0)142 (8.8) Minor effect10,799 (33.4)407 (25.2) Moderate effect9,749 (30.2)696 (43.1) Major effect1,391 (4.3)299 (18.5) Death3 (0.0)3 (0.2) Not followed f4,551 (14.1)68 (4.2) Unknown g7,60584Total (Row %)39,913 (95.9)1,699 (4.1)a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentagesb Unknown age includes “unknown ≤5 years old”c Includes admission to a critical care unit or non-critical care unitd Includes “refused referral” and “did not arrive at a healthcare facility”e Includes individuals lost to follow-up or who left against medical advice, and those admitted to a psychiatric facilityf Includes “not followed (minimal clinical effects possible)” and “not followed (judged as non-toxic exposure)”g Includes “unable to follow (judged as a potentially toxic exposure)” Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by ingestion type, 2000–2024 a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages b Unknown age includes “unknown ≤5 years old” c Includes admission to a critical care unit or non-critical care unit d Includes “refused referral” and “did not arrive at a healthcare facility” e Includes individuals lost to follow-up or who left against medical advice, and those admitted to a psychiatric facility f Includes “not followed (minimal clinical effects possible)” and “not followed (judged as non-toxic exposure)” g Includes “unable to follow (judged as a potentially toxic exposure)” Medical outcome Although approximately half (50.6%) of ingestions were associated with no effect (17.6%) or minor effects (33.0%), 30.8% had moderate effects, 5.0% had major effects, and there were six deaths (Table 1). The proportion of major effects decreased with increasing age, from 7.3% among < 1-year-olds to 3.4% among 5-year-olds. Children < 3 years old were more likely to experience a major effect (RR: 1.54; 95% CI:1.39–1.71) than children 3–5 years old. In addition, multiple-substance ingestions were more likely to be associated with a major effect (18.5%) (RR: 4.30; 95% CI: 3.83–4.82) than single-substance ingestions (4.3%) (Table 2). All six fatalities involved children < 3 years old (Table 1). Three deaths were single-substance and three were multiple-substance ingestions (Table 2). Three fatalities involved non-prescription fentanyl, one involved fentanyl (unknown if prescription or non-prescription fentanyl), and two involved cocaine as the primary substances. The relative contribution to fatality of the primary substances involved in these fatalities were determined to be “probably responsible” or “undoubtedly responsible” by either the PC or America’s Poison Centers. Based on narratives obtained from the reporting PCs, details of these fatalities are as follows. 1) A 10-month-old child ingested cocaine (based on urine drug screen) at home and experienced seizures, tachycardia, hyperthermia, cardiac arrest, and received cardiopulmonary resuscitation, mechanical ventilation, and vasopressors, among other therapies in the critical care unit prior to determination of brain death. 2) A 19-month-old child arrived at the emergency department pulseless and apneic following ingestion of fentanyl (primary substance), tramadol, and cocaine (confirmed postmortem) in a public area. The child also experienced hypothermia and renal failure, and received cardiopulmonary resuscitation, mechanical ventilation, and vasopressors, among other therapies in the critical care unit prior to discontinuation of life support. 3) A 22-month-old child was found unresponsive with difficulty breathing by the family at home and was transferred to the emergency department by emergency medical services. The child experienced asystole and respiratory arrest, and received cardiopulmonary resuscitation, mechanical ventilation, and vasopressors, among other therapies prior to determination of brain death. Postmortem testing revealed fentanyl, norfentanyl, methamphetamine, and amphetamine; the cause of death was listed as fentanyl (primary substance) and methamphetamine. 4) A 2-year-old child, who ingested fentanyl (primary substance) and cocaine (based on urine drug screen), was found unresponsive and apneic at home. Cardiopulmonary resuscitation and endotracheal intubation were performed in the emergency department, followed by transfer to the critical care unit. The child experienced pulseless electrical activity (on arrival to emergency department), asystole, respiratory arrest, seizures, anoxic brain injury with herniation, and received cardiopulmonary resuscitation, mechanical ventilation, and vasopressors, among other therapies prior to determination of brain death. 5) A 14-month-old child experienced seizures and cyanosis at home, followed by a cardiac arrest after arrival of emergency medical services. The child also experienced hypotension and hypothermia, and received cardiopulmonary resuscitation, mechanical ventilation, and vasopressors, among other therapies prior to determination of brain death. Cocaine metabolites were detected by gas chromatography/mass spectrometry testing. 6) A 15-month-old child was found unresponsive at home and was pronounced dead upon hospital arrival. A urine drug screen was positive for fentanyl. Substance category Most (84.7%) ingestions involved cannabinoids, followed by stimulants (8.4%), psychedelics (3.5%), opioids (2.8%), and dissociative agents (0.6%) (Table 1). The proportion of ingestions associated with cannabinoids increased with increasing age, from 66.2% among < 1-year-olds to 91.8% among 5-year-olds. Most ingestions involving cannabinoids (59.8%) and psychedelics (84.1%) did not receive treatment in a healthcare facility or were treated/evaluated and released (Table 3). However, 30.9% of cannabinoid ingestions were medically admitted (including 10.4% to a critical care unit) and 10.3% of psychedelic ingestions were admitted (including 3.5% to a critical care unit). This was in contrast to ingestions involving stimulants (46.8% admission, including 23.5% critical care), opioids (46.3% admission, including 29.8% critical care), and dissociative agents (42.2% admission, including 19.1% critical care). Opioid ingestions (RR: 1.46; 95% CI: 1.37–1.56) and stimulant ingestions (RR: 1.53; 95% CI: 1.46–1.59) were more likely to be associated with medical admission than the other substance categories combined. In addition, ingestions involving opioids (RR: 2.60; 95% CI: 2.36–2.86), stimulants (RR: 2.16; 95% CI: 2.01–2.31), and dissociative agents (RR: 1.59; 95% CI: 1.23–2.06) were more likely to be admitted to a critical care unit than the other substance categories combined. Table 3Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States Poison Centers by substance category, 2000–2024CharacteristicsSubstance CategoriesCannabinoidsn (%) aStimulantsn (%) aPsychedelicsn (%) aOpioidsn (%) aDissociative agentsn (%) aChild Sex Male17,628 (50.6)1,865 (54.1)763 (53.2)633 (54.7)136 (51.3) Female17,241 (49.5)1,582 (45.9)671 (46.8)524 (45.3)129 (48.7) Unknown3684120101Ingestion Type Single-substance34,260 (97.2)3,099 (88.9)1,418 (97.5)922 (79.0)214 (80.5) Multiple-substance977 (2.8)389 (11.2)36 (2.5)245 (21.0)52 (19.6)Highest Level of Health Care Received No treatment received in a health care facility5,393 (18.5)412 (12.9)662 (51.3)254 (22.9)66 (26.3) Treated/evaluated and released12,051 (41.3)1,145 (35.8)423 (32.8)319 (28.7)69 (27.5) Medical Admission b9,023 (30.9)1,496 (46.8)133 (10.3)514 (46.3)106 (42.2) Admitted to a critical care unit3,048 (10.4)751 (23.5)45 (3.5)331 (29.8)48 (19.1) Admitted to a non-critical care unit5,975 (20.5)745 (23.3)88 (6.8)183 (16.5)58 (23.1) Refused referral c2,748 (9.4)143 (4.5)72 (5.6)24 (2.2)10 (4.0) Other/Unknown d6,0222921645615Medical Outcome No effect4,407 (15.6)756 (24.5)478 (38.0)254 (23.4)62 (25.2) Minor effect10,245 (36.3)598 (19.4)208 (16.5)107 (9.8)48 (19.5) Moderate effect8,845 (31.3)1,109 (35.9)178 (14.2)254 (23.4)59 (24.0) Major effect1,071 (3.8)282 (9.1)10 (0.8)300 (27.6)27 (11.0) Death0 (0.0)2 (0.1)0 (0.0)4 (0.4)0 (0.0) Not followed e3,678 (13.0)340 (11.0)383 (30.5)168 (15.5)50 (20.3) Unknown f6,9914011978020Total (Row %)35,237 (84.7)3,488 (8.4)1,454 (3.5)1,167 (2.8)266 (0.6)a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentagesb Includes admission to a critical care unit or non-critical care unitc Includes “refused referral” and “did not arrive at a healthcare facility”d Includes individuals lost to follow-up or who left against medical advice, and those admitted to a psychiatric facilitye Includes “not followed (minimal clinical effects possible)” and “not followed (judged as non-toxic exposure)”f Includes “unable to follow (judged as a potentially toxic exposure)” Table 3Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States Poison Centers by substance category, 2000–2024CharacteristicsSubstance CategoriesCannabinoidsn (%) aStimulantsn (%) aPsychedelicsn (%) aOpioidsn (%) aDissociative agentsn (%) aChild Sex Male17,628 (50.6)1,865 (54.1)763 (53.2)633 (54.7)136 (51.3) Female17,241 (49.5)1,582 (45.9)671 (46.8)524 (45.3)129 (48.7) Unknown3684120101Ingestion Type Single-substance34,260 (97.2)3,099 (88.9)1,418 (97.5)922 (79.0)214 (80.5) Multiple-substance977 (2.8)389 (11.2)36 (2.5)245 (21.0)52 (19.6)Highest Level of Health Care Received No treatment received in a health care facility5,393 (18.5)412 (12.9)662 (51.3)254 (22.9)66 (26.3) Treated/evaluated and released12,051 (41.3)1,145 (35.8)423 (32.8)319 (28.7)69 (27.5) Medical Admission b9,023 (30.9)1,496 (46.8)133 (10.3)514 (46.3)106 (42.2) Admitted to a critical care unit3,048 (10.4)751 (23.5)45 (3.5)331 (29.8)48 (19.1) Admitted to a non-critical care unit5,975 (20.5)745 (23.3)88 (6.8)183 (16.5)58 (23.1) Refused referral c2,748 (9.4)143 (4.5)72 (5.6)24 (2.2)10 (4.0) Other/Unknown d6,0222921645615Medical Outcome No effect4,407 (15.6)756 (24.5)478 (38.0)254 (23.4)62 (25.2) Minor effect10,245 (36.3)598 (19.4)208 (16.5)107 (9.8)48 (19.5) Moderate effect8,845 (31.3)1,109 (35.9)178 (14.2)254 (23.4)59 (24.0) Major effect1,071 (3.8)282 (9.1)10 (0.8)300 (27.6)27 (11.0) Death0 (0.0)2 (0.1)0 (0.0)4 (0.4)0 (0.0) Not followed e3,678 (13.0)340 (11.0)383 (30.5)168 (15.5)50 (20.3) Unknown f6,9914011978020Total (Row %)35,237 (84.7)3,488 (8.4)1,454 (3.5)1,167 (2.8)266 (0.6)a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentagesb Includes admission to a critical care unit or non-critical care unitc Includes “refused referral” and “did not arrive at a healthcare facility”d Includes individuals lost to follow-up or who left against medical advice, and those admitted to a psychiatric facilitye Includes “not followed (minimal clinical effects possible)” and “not followed (judged as non-toxic exposure)”f Includes “unable to follow (judged as a potentially toxic exposure)” Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States Poison Centers by substance category, 2000–2024 a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages b Includes admission to a critical care unit or non-critical care unit c Includes “refused referral” and “did not arrive at a healthcare facility” d Includes individuals lost to follow-up or who left against medical advice, and those admitted to a psychiatric facility e Includes “not followed (minimal clinical effects possible)” and “not followed (judged as non-toxic exposure)” f Includes “unable to follow (judged as a potentially toxic exposure)” Although most ingestions involving cannabinoids (51.9%) and psychedelics (54.4%) were associated with no or minor effects, 3.8% of cannabinoid ingestions and 0.8% of psychedelic ingestions were associated with major effects (Table 3). This was in contrast to ingestions involving opioids (27.6% major effects), dissociative agents (11.0% major effects), and stimulants (9.1% major effects). Opioid ingestions (RR: 6.52; 95% CI: 5.85–7.27), dissociative agent ingestions (RR: 2.22; 95% CI: 1.55–3.18), and stimulant ingestions (RR: 2.00; 95% CI: 1.77–2.26) were more likely to be associated with a major effect than the other substance categories combined. Substance subcategory Marijuana products accounted for 77.0% of ingestions among children < 6 years old, including edible preparations which accounted for 47.9% of all ingestions (Table 4). The proportion of ingestions attributable to marijuana increased with increasing age, from 63.6% among < 1-year-olds to 82.2% among 5-year-olds; the same pattern was seen for marijuana edibles specifically. Semi-synthetic cannabinoids accounted for 7.0% of ingestions, with the proportion also increasing with increase in age. Marijuana edible preparations accounted for 32.8% (n = 555) of major effects and 44.2% (n = 4,982) of medical admissions. Compared with all other substances, marijuana edible ingestions were less likely to be associated with a major effect (RR: 0.55; 95% CI: 0.50–0.61), medical admission (RR: 0.90; 95% CI: 0.88–0.93), or critical care unit admission (RR: 0.74; 95% CI: 0.69–0.78). Table 4Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by child age and substance categories and subcategories, 2000–2024Substance Categories and SubcategoriesChild Age< 1 Yearn (%) a1 Yearn (%) a2 Yearsn (%) a3 Yearsn (%) a4 Yearsn (%) a5 Yearsn (%) aUnknown b n Totaln (%) aCannabinoids2,328 (66.2)7,472 (77.9)9,382 (86.8)7,329 (90.1)5,104 (91.3)3,528 (91.8)9435,237 (84.7) Marijuana2,237 (63.6)6,967 (72.6)8,456 (78.2)6,565 (80.7)4,562 (81.6)3,160 (82.2)8932,033 (77.0) Edible preparations335 (9.5)3,029 (31.6)5,742 (53.1)4,910 (60.4)3,473 (62.1)2,418 (62.9)4019,947 (47.9) Other preparations1,902 (54.1)3,938 (41.0)2,714 (25.1)1,655 (20.4)1,089 (19.5)742 (19.3)4612,086 (29.0) Semi-synthetic cannabinoids44 (1.3)417 (4.4)861 (8.0)712 (8.8)511 (9.1)347 (9.0)52,897 (7.0)Synthetic cannabinoids47 (1.3)88 (0.9)65 (0.6)52 (0.6)31 (0.6)21 (0.6)3307 (0.7)Stimulants751 (21.4)1,223 (12.7)770 (7.1)377 (4.6)215 (3.9)132 (3.4)203,488 (8.4) Cocaine239 (6.8)489 (5.1)287 (2.7)145 (1.8)67 (1.2)56 (1.5)51,288 (3.1) Methamphetamine434 (12.3)597 (6.2)362 (3.4)176 (2.2)117 (2.1)56 (1.5)121,754 (4.2) Hallucinogenic amphetamines78 (2.2)137 (1.4)121 (1.1)56 (0.7)31 (0.6)20 (0.5)3446 (1.1)Psychedelics106 (3.0)366 (3.8)342 (3.2)297 (3.7)199 (3.6)137 (3.6)71,454 (3.5) Lysergic acid diethylamide9 (0.3)32 (0.3)47 (0.4)22 (0.3)25 (0.5)9 (0.2)2146 (0.4) Psilocybin and psilocin-containing mushrooms and processed products66 (1.9)289 (3.0)259 (2.4)244 (3.0)164 (2.9)106 (2.8)31,131 (2.7) Peyote/mescaline31 (0.9)45 (0.5)36 (0.3)31 (0.4)10 (0.2)22 (0.6)2177 (0.4)Opioids282 (8.0)436 (4.5)253 (2.3)103 (1.3)57 (1.0)34 (0.9)21,167 (2.8) Heroin75 (2.1)136 (1.4)112 (1.0)49 (0.6)28 (0.5)14 (0.4)1415 (1.0) Fentanyl207 (5.9)300 (3.1)141 (1.3)54 (0.7)29 (0.5)20 (0.5)1752 (1.8)Dissociative Agents49 (1.4)99 (1.0)64 (0.6)25 (0.3)16 (0.3)13 (0.3)0266 (0.6) Ketamine and analogs1 (0.0)25 (0.3)16 (0.2)2 (0.0)2 (0.0)2 (0.1)048 (0.1) Phenylcyclohexylpiperidine48 (1.4)74 (0.8)48 (0.4)23 (0.3)14 (0.3)11 (0.3)0218 (0.5)Total (Row %) c3,516 (8.5)9,596 (23.1)10,811 (26.1)8,131 (19.6)5,591 (13.5)3,844 (9.3)12341,612 (100.0)a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentagesb Unknown age includes “unknown ≤5 years old”c Row percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages Table 4Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by child age and substance categories and subcategories, 2000–2024Substance Categories and SubcategoriesChild Age< 1 Yearn (%) a1 Yearn (%) a2 Yearsn (%) a3 Yearsn (%) a4 Yearsn (%) a5 Yearsn (%) aUnknown b n Totaln (%) aCannabinoids2,328 (66.2)7,472 (77.9)9,382 (86.8)7,329 (90.1)5,104 (91.3)3,528 (91.8)9435,237 (84.7) Marijuana2,237 (63.6)6,967 (72.6)8,456 (78.2)6,565 (80.7)4,562 (81.6)3,160 (82.2)8932,033 (77.0) Edible preparations335 (9.5)3,029 (31.6)5,742 (53.1)4,910 (60.4)3,473 (62.1)2,418 (62.9)4019,947 (47.9) Other preparations1,902 (54.1)3,938 (41.0)2,714 (25.1)1,655 (20.4)1,089 (19.5)742 (19.3)4612,086 (29.0) Semi-synthetic cannabinoids44 (1.3)417 (4.4)861 (8.0)712 (8.8)511 (9.1)347 (9.0)52,897 (7.0)Synthetic cannabinoids47 (1.3)88 (0.9)65 (0.6)52 (0.6)31 (0.6)21 (0.6)3307 (0.7)Stimulants751 (21.4)1,223 (12.7)770 (7.1)377 (4.6)215 (3.9)132 (3.4)203,488 (8.4) Cocaine239 (6.8)489 (5.1)287 (2.7)145 (1.8)67 (1.2)56 (1.5)51,288 (3.1) Methamphetamine434 (12.3)597 (6.2)362 (3.4)176 (2.2)117 (2.1)56 (1.5)121,754 (4.2) Hallucinogenic amphetamines78 (2.2)137 (1.4)121 (1.1)56 (0.7)31 (0.6)20 (0.5)3446 (1.1)Psychedelics106 (3.0)366 (3.8)342 (3.2)297 (3.7)199 (3.6)137 (3.6)71,454 (3.5) Lysergic acid diethylamide9 (0.3)32 (0.3)47 (0.4)22 (0.3)25 (0.5)9 (0.2)2146 (0.4) Psilocybin and psilocin-containing mushrooms and processed products66 (1.9)289 (3.0)259 (2.4)244 (3.0)164 (2.9)106 (2.8)31,131 (2.7) Peyote/mescaline31 (0.9)45 (0.5)36 (0.3)31 (0.4)10 (0.2)22 (0.6)2177 (0.4)Opioids282 (8.0)436 (4.5)253 (2.3)103 (1.3)57 (1.0)34 (0.9)21,167 (2.8) Heroin75 (2.1)136 (1.4)112 (1.0)49 (0.6)28 (0.5)14 (0.4)1415 (1.0) Fentanyl207 (5.9)300 (3.1)141 (1.3)54 (0.7)29 (0.5)20 (0.5)1752 (1.8)Dissociative Agents49 (1.4)99 (1.0)64 (0.6)25 (0.3)16 (0.3)13 (0.3)0266 (0.6) Ketamine and analogs1 (0.0)25 (0.3)16 (0.2)2 (0.0)2 (0.0)2 (0.1)048 (0.1) Phenylcyclohexylpiperidine48 (1.4)74 (0.8)48 (0.4)23 (0.3)14 (0.3)11 (0.3)0218 (0.5)Total (Row %) c3,516 (8.5)9,596 (23.1)10,811 (26.1)8,131 (19.6)5,591 (13.5)3,844 (9.3)12341,612 (100.0)a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentagesb Unknown age includes “unknown ≤5 years old”c Row percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages Characteristics of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by child age and substance categories and subcategories, 2000–2024 a Column percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages b Unknown age includes “unknown ≤5 years old” c Row percentages may not add to 100.0% due to rounding error. Unknown cases were not included in the denominator when calculating percentages Methamphetamine was the most common subcategory among stimulants and accounted for 4.2% of ingestions in this study, followed by cocaine (3.1%) and hallucinogenic amphetamines (1.1%) (Table 4). These proportions for each stimulant subcategory decreased with increasing age. Methamphetamine was more likely to be associated with a major effect (RR: 1.59; 95% CI: 1.34–1.90), medical admission (RR: 1.74; 95% CI: 1.66–1.83), or a critical care unit admission (RR: 2.24; 95% CI: 2.05–2.45) than all other substances combined. Likewise, cocaine was more likely to be associated with a major effect (RR: 2.34; 95% CI: 1.97–2.77), medical admission (RR: 1.30; 95% CI: 1.21–1.39), or a critical care unit admission (RR: 1.82; 95% CI: 1.63–2.04) than all other substances combined. Among opioids, fentanyl accounted for 1.8% of ingestions among children < 6 years old and heroin accounted for 1.0% (Table 4). These proportions decreased with increasing age. Fentanyl was more likely to be associated with a major effect (RR: 7.74; 95% CI: 6.90–8.68), medical admission (RR: 1.75; 95% CI: 1.63–1.87), or a critical care unit admission (RR: 3.14; 95% CI: 2.84–3.48) than all other substances combined. Psilocybin and psilocin-containing mushrooms and processed products was the most common psychedelics subcategory and accounted for 2.7% of ingestions among children < 6 years old (Table 4). Compared with all other substances, psilocybin and psilocin-containing mushrooms and processed product ingestions were less likely to be associated with a major effect (RR: 0.10; 95% CI: 0.04–0.24), medical admission (RR: 0.27; 95% CI: 0.22–0.33), or critical care unit admission (RR: 0.25; 95% CI: 0.18–0.36). Phenylcyclohexylpiperidine was the most common dissociative agent subcategory and accounted for 0.5% of ingestions in this study, followed by ketamine and analogs (0.1%). Time trends There was a 3,307.2% nonlinear increase in the rate of recreational drug ingestions per 100,000 US children < 6 years old from 1.05 in 2000 to 35.91 in 2024. Starting in 2013, the rate increased rapidly by 2,286.2% from 1.51 in 2013 to 35.91 2024 (P < 0.0001) (Fig. 1). Rates and rate trends were similar for males and females across the study period. Children < 3 years old experienced higher ingestion rates than children 3–5 years old throughout the study period (Fig. 2). The ingestion rate among children < 3 years old increased by 1,580.7% from 2.28 in 2013 to 38.32 in 2024 (P < 0.0001), and the rate among children 3–5 years old increased by 4,418.9% from 0.74 in 2013 to 33.44 in 2024 (P < 0.0001). Fig. 1Annual rate of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by child sex, 2000–2024 Annual rate of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by child sex, 2000–2024 Fig. 2Annual rate of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by age group, 2000–2024 Annual rate of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by age group, 2000–2024 With the exception of dissociative agents, all substance categories experienced statistically significant increases in ingestion rates from 2000 to 2024, with rapid increases observed during the latter half of the study period (Fig. 3). In particular, the rate of cannabinoid ingestions increased by 2,348.9% from 1.37 in 2015 to 33.55 in 2024 (P < 0.0001). This increase in cannabinoid ingestions was driven by the ingestion rate of marijuana edible preparations, which rapidly grew from 0.05 in 2013 (when the first marijuana edible ingestion was reported in this study) to 20.99 in 2024 (P < 0.0001). Although the rate of marijuana edibles exceeded that of other preparations starting in 2019, the rate of the latter also increased by 1,460.4% from 0.48 in 2010 to 7.49 in 2024 (P < 0.0001) (Fig. 4). Fig. 3Annual rate of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by substance category, 2000–2024 Annual rate of ingestions involving recreational drugs among children younger than six years old reported to United States poison centers by substance category, 2000–2024 Fig. 4Annual rate of ingestions involving marijuana preparations among children younger than six years old reported to United States poison centers by marijuana subcategory, 2000–2024. Note: The first ingestion of an edible marijuana preparation in this study was reported in 2013 Annual rate of ingestions involving marijuana preparations among children younger than six years old reported to United States poison centers by marijuana subcategory, 2000–2024. Note: The first ingestion of an edible marijuana preparation in this study was reported in 2013 The rate of ingestions involving psychedelics demonstrated a nonlinear trend pattern from 2000 to 2018, followed by a 827.3% increase from 0.11 in 2018 to 1.02 in 2024 (P < 0.0001) (Fig. 3). This trend pattern of psychedelic ingestions was driven by psilocybin and psilocin-containing mushrooms and processed products, which experienced a 1,466.7% increase from 0.06 in 2018 to 0.94 in 2024 (P < 0.0001) (Fig. 5). Fig. 5Annual rate of ingestions involving psychedelics among children younger than six years old reported to United States poison centers by psychedelic subcategory, 2000–2024 Annual rate of ingestions involving psychedelics among children younger than six years old reported to United States poison centers by psychedelic subcategory, 2000–2024 The stimulant ingestion rate increased nonlinearly overall during the study period by 113.5% from 0.37 in 2000 to 0.79 in 2024, reaching its highest rate of 0.95 in 2021 (Fig. 3). This increase in stimulant ingestions was primarily influenced by the rate of methamphetamine ingestions, which increased nonlinearly by 320.0% from 0.10 in 2000 to 0.42 in 2024, reaching its highest rate of 0.67 in 2021 (Fig. 6). Fig. 6Annual rate of ingestions involving stimulants among children younger than six years old reported to United States poison centers by stimulant subcategory, 2000–2024 Annual rate of ingestions involving stimulants among children younger than six years old reported to United States poison centers by stimulant subcategory, 2000–2024 The opioids ingestion rate demonstrated a steady 525.0% increase from 0.04 in 2000 to 0.25 in 2019 (P < 0.0001), followed by a rapid 208.0% increase to 0.77 in 2021 (P < 0.0001) and then a subsequent nonlinear 39.0% decline to 0.47 in 2024 (Fig. 3). The rise in opioid ingestions starting after 2019 was driven by fentanyl, which increased by 285.7% from 0.14 in 2019 to 0.54 in 2021, followed by a 27.8% nonlinear decrease to 0.39 in 2024. The first fentanyl ingestion in this study was reported in 2010 (Fig. 7). Fig. 7Annual rate of ingestions involving opioids among children younger than six years old reported to United States poison centers by opioid subcategory, 2000–2024. Note: The first fentanyl ingestion in this study was reported in 2010 Annual rate of ingestions involving opioids among children younger than six years old reported to United States poison centers by opioid subcategory, 2000–2024. Note: The first fentanyl ingestion in this study was reported in 2010 The rate of medical admissions associated with recreational drug ingestions per 100,000 US children < 6 years old remained relatively unchanged from 2000 to 2015 (P = 0.2390), followed by a rapid 1,531.8% increase from 0.66 in 2015 to 10.77 in 2024 (P < 0.0001) (Fig. 8). The rate of non-critical care unit admissions was higher and demonstrated a greater increase than the rate of critical care unit admissions during the study period. The increase in the rate of medical admissions from 2015 to 2024 was primarily driven by the admission rate for cannabinoids, which increased by 2,529.0% from 0.38 in 2015 to 9.99 in 2024 (P < 0.0001) (Fig. 9). Similarly, the rate of opioid-related medical admissions increased by 1,466.7% from 0.03 in 2015 to 0.47 in 2021 (P < 0.0001); however, it then decreased nonlinearly by 51.1% to 0.23 in 2024. The rate of psychedelic-related medical admissions was relatively stable from 2000 to 2019, followed by a 1,600.0% increase from 0.01 in 2019 to 0.17 in 2024 (P < 0.0001). The rate of stimulant-related medical admissions demonstrated a nonlinear 333.3% increase from 0.12 in 2000 to 0.52 in 2021, followed by a 28.8% decrease to 0.37 in 2024. Fig. 8Annual rate of medical admissions and major effects associated with ingestions of recreational drugs among children younger than six years old reported to United States poison centers, 2000–2024 Annual rate of medical admissions and major effects associated with ingestions of recreational drugs among children younger than six years old reported to United States poison centers, 2000–2024 Fig. 9Annual rate of medical admissions associated with ingestions of recreational drugs among children younger than six years old reported to United States poison centers by substance category, 2000–2024 Annual rate of medical admissions associated with ingestions of recreational drugs among children younger than six years old reported to United States poison centers by substance category, 2000–2024 The rate of major effects associated with recreational drug ingestions per 100,000 US children < 6 years old remained relatively stable from 2000 to 2016, followed by a significant increase by 1,788.9% from 0.09 in 2016 to 1.70 in 2024 (P < 0.0001) (Fig. 8). This increase was primarily driven by cannabinoids, which increased by 27,800.0% from 0.05 in 2016 to 1.44 in 2024 (P < 0.0001) (Fig. 10). The rate of stimulant-related major effects also increased nonlinearly by 3,500.0% from 0.02 in 2016 to 0.09 in 2024. In addition, the rate of opioid-related major effects increased by 8,150.0% from 0.004 in 2016 to 0.33 in 2021 (P < 0.0001), followed by a 51.5% decrease to 0.16 in 2024 (P = 0.1930). Fig. 10Annual rate of major effects associated with ingestions of recreational drugs among children younger than six years old reported to United States poison centers 2000–2024 by substance category, 2000–2024 Annual rate of major effects associated with ingestions of recreational drugs among children younger than six years old reported to United States poison centers 2000–2024 by substance category, 2000–2024 Discussion There were approximately 41,600 recreational drug ingestions among children < 6 years old reported to US PCs from 2000 to 2024, and the rate of ingestion increased by 3,307.2% during these years. The ingestion rate was highest among children < 3 years old, which is a developmental time period associated with increased mobility, exploration of the environment, and placing objects in the mouth [25, 26]. Imitation of adult behavior is also common among toddlers [27], which may further contribute to ingestions in this age group. Children < 3 years old were more likely to experience a major effect, be medically admitted, and specifically, admitted to a critical care unit, than children 3–5 years old. In addition, the six fatalities in this study were among < 3-year-old children. The lower body weight of a younger child may have contributed to the observed higher severity because ingestion of any amount results in a higher relative dose (mg/kg) in younger children. However, weight-based drug dose was not analyzed in this study. In addition, poor communication ability leading to delays in treatment in this age group may have been a contributing factor [28]. Most ingestions in this study involved cannabinoids, with edible marijuana preparations representing almost half of all ingestions. The rate of cannabinoid ingestions increased by > 2,300% from 2015 to 2024, which was driven by edible marijuana preparations (the ingestion rate for edible marijuana preparations exceeded that of other marijuana preparations starting in 2019) and is consistent with trends previously reported [2, 3, 5, 13, 29]. An increase in cannabis exposures among young children has been described in association with the onset of the COVID-19 pandemic [13, 29]. Our study demonstrates that the increasing trend has continued beyond the pandemic, and may, in part, be associated with growing state legalization of cannabis and increased availability of cannabis products in the home [30]. Although opioids accounted for only 2.8% of ingestions in this study, their ingestion rate increased from 2000 to 2021 and they were associated with more severe outcomes. Fentanyl was involved with almost two-thirds of opioid ingestions and was more than seven times more likely to be associated with a major effect and more than three times more likely to be associated with admission to a critical care unit than the other substances combined. Four of the six fatalities in our study were attributed to fentanyl. Previous studies have demonstrated the increasingly prominent role of opioids in pediatric poison-related intensive care unit admissions and fatalities [12, 25, 26, 31]. The rate of opioid ingestions in this study increased until 2021, and then decreased to 2024. The reasons for this change in trend cannot be determined from the NPDS database; however, other authors have noted decreases among the general population in recent years in opioid prescription rates, fentanyl-related nonfatal emergency department visits, and illegally manufactured fentanyl-related deaths [32–34]. There is a known association between prescription of opioids to adults and subsequent opioid exposures in children [35]. In addition, the increased time spent at home by family members during the COVID-19 pandemic may have affected exposure rates. Stimulant ingestions accounted for 8.4% of ingestions and were twice as likely to be associated with admission to a critical care unit and twice as likely to be associated with a major effect than the other substance categories combined. These associations with critical care unit admission and major effects were also observed for both the methamphetamine and cocaine substance subcategories. Two of the six fatalities in this study were associated with cocaine ingestions. The increase in the rate of stimulant ingestions from 2012 to 2021 (which was primarily driven by the increase in methamphetamine ingestions during those years) parallels the increase in stimulant-related overdose deaths in the US since 2011 [36]. It also mirrors the increase in methamphetamine use, methamphetamine use disorder, and psychostimulant-related overdose deaths (primarily attributable to methamphetamine) from 2015 to 2019 among adults reported by Han, et al. [37]. Although dissociative agents accounted for only 0.6% of ingestions, when compared with the other substance categories combined, they were more than 1.5 times more likely to be associated with admission to a critical care unit and more than twice as likely to be associated with a major effect. There has been an increase in ketamine use, both recreationally and for management of mental health disorders, in recent years [38–40]. This may result in increased availability of ketamine in the home, highlighting the need for actions to prevent unintentional pediatric ingestions. Two NPDS-based studies previously reported psilocybin exposures among 13-25-year-olds [14] or all age groups [15]; however, we are unaware of any prior national studies that have focused on psilocybin exposures among children < 6 years old as was done in our study. We found that psychedelic agents represented 3.5% of ingestions, and there was a rapid increase in the rate of psychedelic ingestions from 2018 to 2024, with the rate in 2023 and 2024 exceeding that of all other recreational drugs except cannabinoids. This rate increase was attributable to psilocybin and psilocin-containing mushroom products. This finding is consistent with those of several studies reporting an increase in law enforcement seizures of psilocybin, psilocybin use, and psilocybin-related PC reports in recent years [14–16, 41]. Psilocybin reports to PCs are likely to continue to increase as its use for treatment of mental health disorders grows [42]. Although most psychedelic ingestions in this study were associated with no or minor effects, 10% were admitted, and more severe effects have been reported [43]. Independent testing of recreational psychoactive mushroom gummy and chocolate products has also identified inaccuracies and inconsistencies in product labeling [44] and the presence of substances found in psychoactive mushrooms (i.e., muscimol and psilocin), the kava plant (i.e., kavalactones), acetylpsilocin, and pregabalin [45]. Because processed mushroom products often are coded as psilocybin exposures in the NPDS, this may lead to an over-estimation of psilocybin exposures and misattribution of the related clinical effects and outcomes of these exposures to psilocybin. Because 96% of exposures in our study occurred in a residence and young children rely on adults to provide a safe environment, parent and child caregiver education should emphasize keeping recreational drugs out of the home, or at a minimum, stored up, away, and out of sight and reach of children, preferably in a locked location. Adults should avoid consuming these products in the presence of young children because they often mimic adult behavior. Edible preparations of recreational drugs may be appealing to toddlers because they resemble candy or food, and they often contain multiple servings in one package [10, 29]. Prevention strategies include requirements for opaque, child-resistant packaging with limits on the total dose contained in each serving and the number of servings per package, single-serving packaging, and appropriate labeling [46, 47]. Given the increase in legalization of cannabis and psilocybin for recreational and medical purposes [30, 41], access to these products in the home by young children is likely to continue, underscoring the need for increased prevention efforts. Study limitations The NPDS database relies on self-reporting of exposures; therefore, reporting is incomplete, potentially subject to reporting bias, and PCs and America’s Poison Centers are not able to completely verify the information. Miscoding or misclassification of data may occur, including the determination of the primary substance in multiple-substance ingestions. We excluded 3% of multiple-substance exposures that included one of the selected recreational drugs that was not ranked as the primary substance, and although this was done to decrease the number of incidental recreational drug exposures, it may have resulted in an underrepresentation of true exposures and a severity bias regarding the recreational drug exposures included in this study. Route of exposure may also be misclassified; for example, personnel in one PC may assume that a young child with laboratory-confirmed exposure to a recreational drug was exposed via ingestion while personnel at another PC may not assume this and code the route of exposure as unknown. Our study did not include exposures if the route of exposure was coded as unknown; therefore, we may have missed some true ingestion exposures. In fact, there are two deaths reported in NPDS annual reports during the study years involving young children (two and five years old) who died following exposure via an unknown route to cocaine and methamphetamine, respectively [48, 49]. These deaths were not included in our study. In addition, information about laboratory confirmation of the involved substances was not included in the study dataset. The NPDS does not include personal identifiers; therefore, it is possible that individuals may appear more than once in the dataset if they were involved in more than one separate exposure event. Cases that were not followed or were unable to be followed to a known medical outcome may have introduced bias. Potential confounding may be present in calculation of the unadjusted RRs in this study. Reported ingestions do not necessarily represent a poisoning or overdose. Weight-based drug dose was not analyzed in this study. This study included a selected group of recreational drug categories and therefore does not represent the entire spectrum or magnitude of the problem. Variability in manufacture, labeling, and inadequate or lack of product testing may have led to exposures to other unknown substances not captured by NDPS coding, and these substances may have varied over time with changes in the recreational drug supply. The NPDS creates new generic and product codes in response to the evolving availability of new psychoactive drugs, with product codes generally appearing before generic codes. The changes in these codes may have influenced the observed trends in this study. For example, the generic code for marijuana edible preparations was established in 2016, while the first ingestion of an edible marijuana product in this study was identified in 2013 based on product coding. It is likely that exposures to these products during earlier years were not identified in the NPDS database because no specific code existed. Despite its limitations, the NPDS database is useful for investigating toxic exposures nationally. Conclusions Recreational drug ingestions among children < 6 years old reported to US PCs increased substantially from 2000 to 2024. Increases were especially pronounced for edible marijuana and psilocybin products. Additional efforts are needed to prevent these unintentional ingestions among this vulnerable population, including education of parents and caregivers, promotion of safe storage practices, PC and public health outreach, and implementation and enforcement of child safety-focused public policy at the local to federal levels. Supplementary Information Supplementary Material 1: Appendix. Marijuana Product Codes Included in the Study. Supplementary Material 1: Appendix. Marijuana Product Codes Included in the Study.